Trial Profile
Effects of adalimumab (Humira) on biomarkers in skin and synovial tissue in patients with psoriatic arthritis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Apr 2016
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Psoriatic arthritis
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- Acronyms ADAPs
- 01 Aug 2009 Status changed from recruiting to completed based on publication of results
- 01 Aug 2009 Results were published in the Annals of the Rheumatic Diseases.
- 03 Jan 2007 New trial record.